Tumor necrosis factor-a (TNFa) activates both cell death and cell survival pathways, which render most cancer cells resistant to its cytotoxicity. In this study, we found that pretreatment with luteolin, a plant flavonoid, greatly sensitized TNFa-induced apoptotic cell death in a number of human cancer cell lines; including colorectal cancer COLO205, HCT116 cells and cervical cancer HeLa cells. In the search of the molecular mechanisms responsible for the sensitization effect of luteolin, we discovered that luteolin inhibited TNFa-induced activation of nuclear transcription factor-kappa B (NF-jB), the main survival factor in TNFa signaling. As a result, luteolin suppressed the expression of NF-jB-targeted antiapoptotic genes, including A20 and cellular inhibitor of apoptosis protein-1 (c-IAP1). The role of A20 and c-IAP1 was further confirmed by ectopic expression of these two genes, which significantly protected cell death induced by luteolin followed by TNFa. In addition, inhibition of NF-jB by luteolin led to augmentation and prolongation of c-Jun N-terminal kinase (JNK) activation induced by TNFa. Suppression of JNK activation, either by a synthetic JNK inhibitor (SP600125) or by overexpression of the dominant negative forms of JNK kinase 1 (JNKK1) and JNK kinase 2 (JNKK2), conferred significant protection against apoptotic cell death induced by luteolin and TNFa, suggesting that NF-jB and JNK are closely associated with the sensitization effect of luteolin. Data from this study reveal a novel function of luteolin and enhance the value of luteolin as an anticancer agent.
Introduction
Tumor necrosis factor (TNF) is a proinflammatory cytokine with a wide spectrum of functions in many biological processes, including cell growth and cell death, development, oncogenesis, immunity, inflammatory and stress responses (Tracey and Cerami, 1993) .
The bioactivities of TNF are mainly elicited by TNF receptor 1 (TNFR1), via the following three distinct signaling pathways: (i) nuclear transcription factorkappa B (NF-kB), (ii) mitogen-activated protein kinase c-Jun N-terminal kinase (JNK) and (iii) a caspase cascade (Chen and Goeddel, 2002) . Upon TNF binding, the trimerized TNFR1 first recruits a key adaptor protein TNF receptor-associated death domain (TRADD), which then binds to cytosolic proteins such as receptor-interacting protein (RIP), TNF receptorassociated factor 2 (TRAF2) and Fas-associated death domain (FADD) . It has been well established that the recruitment of FADD into the signaling complex leads to the activation of a caspase cascade and apoptosis (Chinnaiyan et al., 1995; Yeh et al., 1998) . On the other hand, the recruitment of receptor-interacting protein (RIP) and TRAF2 results in the activation of NF-kB which mainly functions as a cell survival mechanism to protect cells against TNFa-induced apoptosis (Ting et al., 1996; Reinhard et al., 1997; Kelliher et al., 1998) . As TNFa activates both cell death and cell survival pathways simultaneously, most cancer cells are resistant to TNFa-induced apoptosis and thus inhibition of NF-kB activation becomes a popular strategy to enhance the sensitivity of cancer cells to apoptosis mediated by TNF family proteins (Baldwin, 2001; Yamamoto and Gaynor, 2001) .
NF-kB is a ubiquitous transcription factor consisting of heterogenous dimeric proteins containing a Rel homology domain (Karin and Delhase, 2000) . In resting cells, NF-kB binds to inhibitor of kB (IkB) proteins and localizes in cytoplasm. In response to TNFa-TNFR1 ligation, the activated IkB kinase (IKK) phosphorylates IkB, which results in the degradation of IkB through ubiquitination. The released NF-kB then translocates from cytoplasm to nuclei and binds to the promoter regions of its target genes to regulate the gene expression. A number of genes such as A20, IAPs, cellular FLICE inhibitory protein (c-FLIP), TRAF1 and TRAF2 have been identified as NF-kB-regulated antiapoptotic genes (Krikos et al., 1992; Wang et al., 1998; Micheau et al., 2001) . In contrast to the well-established antiapoptotic role of NF-kB, the exact function of JNK in TNF-mediated apoptosis remains largely controversial (Liu et al., 1996; Natoli et al., 1997) . Recently, it has been demonstrated that prolonged JNK activation by the suppression of NF-kB activity promotes TNFa-induced apoptosis (Tang et al., 2001; De Smaele et al., 2001 ). It appears that the exact function of JNK in TNF-induced apoptosis depends on a number of factors such as cell type and/or the presence of other signaling pathways such as NF-kB activation (Karin and Lin, 2002) .
Flavonoids are a group of natural polyphenolic compounds widely distributed in the plant kingdom. The bioactivities of flavonoids have been extensively studied, including their antioxidant, anti-inflammatory and anticancer activities (Ross and Kasum, 2002) . The anticancer activity of flavonoids has been well proven in epidemiological investigation and in animal studies, although the exact mechanisms have not been fully understood (Birt et al., 2001; Yang et al., 2001) . Luteolin, 3 0 , 4 0 , 5, 7-tetrahydroxyflavone, is a flavonoid that is commonly found in many types of fruits and vegetables. Currently, there is some preliminary evidence showing the anticancer effect of luteolin. Topical application of luteolin caused significant reduction of skin tumor incidence and multiplicity in a mouse skin cancer model (Ueda et al., 2003) . In in vitro studies, luteolin, as a potent inhibitor of cyclin-dependent kinases, has been found to induce cell cycle arrest in human melanoma cell and apoptotic cell death in human myeloid leukemia cells (Huang et al., 1999; Ko et al., 2002) . In this study, we found that luteolin significantly sensitizes TNFa-induced apoptosis in a number of human cancer cell lines. Such sensitization is closely associated with its inhibitory effect on NF-kB activation, resulting in downregulation of some key antiapoptotic genes, such as A20 and c-IAP1. Luteolin pretreatment also leads to augmented and prolonged JNK activation induced by TNFa, a process that is known to be critical in the sensitization of luteolin on TNFa-induced apoptosis. Therefore, data from this study advance our understanding of the molecular mechanism involved in the anticancer activity of luteolin.
Results

Luteolin sensitizes TNFa-induced cell death in cancer cells
Majority of cancer cells are resistant to TNFa without the blockage of gene transcription and de novo protein synthesis. In this study, human colorectal cancer COLO205 cells were found to be resistant to TNFainduced cytotoxicity, as demonstrated by the lack of sub-G1 cells determined using flow cytometry (Figure 1a) . Similarly, no evident cell death was observed when cells were treated with luteolin alone (40 mM Â 12 h). We next tested the combined effect of luteolin and TNFa and discovered that pretreatment with luteolin (40 mM Â 2 h) greatly sensitized and accelerated COLO205 cells to TNFa-induced cell death. As shown in Figure 1a , more than 60% of cell death occurred after the cells were pretreated with luteolin followed by TNFa treatment as early as 6 h. The sensitizing effect of luteolin on TNFa-induced cell death was also found to be dose dependent. Similar sensitization effect was also found in another human colorectal cancer cell line HCT116 and in human cervix cancer HeLa cells (Figure 1a) , suggesting that the sensitization of luteolin on TNFa -induced cell death may apply to a wide spectrum of cancer types. Furthermore, we noted that the sequence of treatment is important. No sensitization was found when luteolin was added 2 h after TNFa exposure (luteolin post-treatment) (Figure 1b) , indicating that the sensitization effect by luteolin is probably achieved through the blockage of certain cell survival signals elicited by TNFa.
Luteolin sensitizes TNFa-induced cell death through apoptosis
TNFa is capable of inducing either apoptotic or necrotic cell death in certain types of cells (Denecker et al., 2001) . As sub-G1 cells could either be apoptotic or necrotic (Darzynkiewicz et al., 1998) , we then asked whether luteolin sensitizes TNFa-induced cell death via apoptosis. We first examined the morphological changes using AO/EB staining under a fluorescent microscope (McGahon et al., 1995) . In COLO205 cells, treatment with luteolin and TNFa resulted in evident cell shrinkage, cell membrane blebbing, chromatin condensation and formation of apoptotic body at the early stage of cell death (data not shown), indicating that luteolin plus TNFa induces typical apoptotic cell death in this cell line. To confirm the above observations, we further analysed two biochemical hall-markers of apoptosis: PARP cleavage and DNA fragmentation. While neither luteolin nor TNFa alone caused PARP cleavage or DNA fragmentation, luteolin pretreatment followed by TNFa caused PARP cleavage ( Figure 2a ) and DNA fragmentation ( Figure 2b ) in a dose-dependent manner. The extent of these changes was comparable to cells treated with ActD plus TNFa. It is well known that actinomycin D (ActD) and cycloheximide (CHX) are general gene transcription and de novo protein synthesis inhibitors, respectively, which enhance TNFa-induced cell death via unspecific blockage of antiapoptotic gene expression. To test whether luteolin acts through similar mechanisms, we examined the changes of the protein level of c-myc, a short half-life protein in the cell (Salghetti et al., 1999) . As shown in Figure 2c , ActD and CHX but not luteolin reduced the c-myc protein content, indicating that luteolin is not a general gene expression inhibitor.
Luteolin-induced sensitization is associated with enhanced caspase 8 activation
Caspase activation is the central machinery in apoptosis, and TNFa mediates apoptotic cell death via the cell death receptor pathway initiating from caspase 8 activation (Strasser and Newton, 1999) . In this study, no caspase 8 activation was found in COLO205 cells treated with either luteolin or TNFa alone, while luteolin pretreatment markedly enhanced caspase 8 cleavage as well as its activity in TNFa-treated cells (Figure 3a and b). Similar pattern was also observed in subsequent activation of the effector caspase 3 ( Figure  3a and b). In order to confirm the role of such a caspase cascade in apoptosis mediated by luteolin and TNFa, we tested the effect of a specific caspase 8 inhibitor (z-IETD-fmk) as well as a general caspase inhibitor (z-VAD-fmk) on cell death induced by luteolin pretreatment followed by TNFa. Both inhibitors effectively blocked PARP cleavage ( Figure 3c , upper panel) and DNA fragmentation (Figure 3c , lower panel) in cells treated with luteolin and TNFa, in concomitant with caspase 8 and caspase 3 inhibition (Figure 3a) . Similar results were also found in HeLa cells and HCT116 cells treated with luteolin and TNFa (data not shown). These results thus indicate that the apoptosis induced by luteolin and TNFa is mediated via caspase 8 activation.
TNFa-induced NF-kB activation is inhibited by luteolin NF-kB is the main cell survival pathway elicited by TNFa. It has been well established that inhibition of NF-kB signaling pathway sensitizes TNFa-induced cell death (Yamamoto and Gaynor, 2001; Baldwin, 2001) . Luteolin has recently been shown to inhibit LPS-induced NF-kB activation, a mechanism involved in its antiinflammatory activity (Xagorari et al, 2001; Kim et al., 2003b) . In order to understand the underlying mechanism responsible for the sensitization effect of luteolin on TNFa-induced apoptosis, we systematically examined the effects of luteolin on various phases of NF-kB signaling pathways triggered by TNFa. First, we examined the inhibitory effect of luteolin on NF-kB transcriptional activity in COLO205 cells by using the NF-kB luciferase reporter assay. As shown in Figure 4a , treatment with TNFa significantly enhanced NF-kB transcriptional activity and luteolin pretreatment markedly, although not completely, suppressed the transactivation of NF-kB induced by TNFa. A similar inhibitory effect was found with parthenolide, a known specific inhibitor of IKK (Hehner et al., 1999) . The reduced luciferase activity by luteolin may due to its direct inhibition on luciferase enzyme activity. To exclude such a possibility, luteolin post-treatment was conducted. Cells were first treated with TNFa (15 ng/ml) for 2 h followed by luteolin (40 mM) treatment for another 2 h. It is rather interesting to find that luteolin post-treatment failed to inhibit the transactivation of NF-kB induced COLO205 cells were pretreated with the indicated concentrations of luteolin for 2 h followed by TNFa (15 ng/ml) treatment for additional 6 h. ActD (1 mg/ml) pretreatment (1 h) was used as a positive control in both experiments. (c) Changes of c-myc protein level in COLO205 cells treated with luteolin (40 mM), ActD (1 mg/ ml) or CHX (10 ng/ml) for 6 h, detected using Western blotting. The content of tubulin was used as a loading control by TNFa (Figure 4a ), suggesting that luteolin does not suppress NF-kB activation post-transcriptionally and pose no direct inhibition to luciferase enzyme activity.
The activation of NF-kB requires a series of upstream events including degradation of IkBa, NF-kB nuclear translocation and NF-kB-DNA binding (Karin and Ben Neriah, 2000) . To define the mechanism by which luteolin inhibits NF-kB activation, we sought to define whether luteolin affects these upstream events. As shown in Figure 4b , IkBa degradation and p65 nuclear translocation induced by TNFa in COLO205 cells were inhibited by parthenolide, a known specific IKK inhibitor (Hehner et al., 1999) , but not by luteolin. We next examined whether luteolin affects the NF-kB-DNA-binding activity using EMSA. As shown in Figure 4c , p65 was found to be main NF-kB component in TNFa-stimulated cells (supershift assay). Luteolin pretreatment failed to suppress p65-DNA binding, while it was completely abolished by parthenolide. Similar results were obtained when HeLa cells were tested (data not shown).
It is known that transcriptional activation of NF-kB requires the participation of a number of coactivators including cAMP response element-binding protein (CBP) (Gerritsen et al., 1997) . We next examined whether luteolin affects the interaction between p65 and CBP. As shown in Figure 4d , TNFa markedly enhanced CBP-p65 interaction and this interaction was significantly inhibited by luteolin pretreatment, suggesting that luteolin inhibits TNFa-induced NF-kB activation via interfering p65-CBP interaction. Such action of luteolin was found to be similar to its inhibitory effect on LPS-activated NF-kB transcription in fibroblasts (Kim et al., 2003b) . To further confirm the involvement of p65-CBP interaction in luteolin-mediated suppression on NF-kB activation, HeLa cells were transiently transfected with a p65-GFP expression vector. As shown in Figure 4d and e, p65 overexpression significantly overturned the sensitization effect of luteolin and protected against cell death. The above observation also suggests that NF-kB (p65) serves as the molecular target for the sensitization activity of luteolin on TNFainduced apoptosis.
Luteolin suppresses the expression of NF-kB antiapoptotic target genes A20 and cellular inhibitor of apoptosis protein-1 (c-IAP1)
The antiapoptotic function of NF-kB is depending on the expression of various antiapoptotic genes such as IAP, FLIP, A20, Mn-SOD and Bcl-2 family. Here, we further examined whether luteolin pretreatment influences the expression level of those genes. As shown in Figure 5 , TNFa markedly upregulated the expression of A20 and c-IAP1, while luteolin pretreatment significantly reduced their expression level. In contrast, no significant changes of c-IAP2, c-FLIP L and c-FLIP S were noted in cells treated with TNFa or luteolin. No evident upregulation was found for other NF-kB responsible genes such as Bcl-2, Bcl-xl and Mn-SOD upon TNFa exposure (data not shown). Both A20 and c-IAP1 are important antiapoptotic molecules (Wang et al., 1998; He and Ting, 2002) and their reduced expression levels caused by luteolin pretreatment are likely to contribute to the sensitization effect of luteolin on TNFa-induced apoptosis.
JNK activation contributes to the sensitization effect of luteolin on TNFa-induced apoptosis
Although the exact role of JNK in TNF-induced apoptosis is largely controversial, some recent studies have suggested that inhibition of NF-kB resulted in sustained JNK activation and apoptosis (Tang et al., 2001; De Smaele et al., 2001 ). Here, we examined the JNK, luteolin pretreatment significantly augmented and prolonged the JNK activation in TNFa-exposed cells (Figure 6a ). Similar augmentation effect of luteolin on TNFa-mediated JNK activation was also found in HeLa cells (data not shown).
In order to understand the role of JNK activation in apoptosis induced by luteolin and TNFa, we next assessed the effect of a synthetic JNK inhibitor, SP600125 (Bennett et al., 2001) , on JNK activation and cell death in COLO205 cells treated with luteolin and TNFa. As expected, pretreatment with SP600125 prevented luteolin and TNFa-induced JNK activation (Figure 6a ). More importantly, it almost completely blocked the catalytic cleavage of caspase 8 and its downstream effector caspase 3, as well as PARP cleavage (Figure 6b ), suggesting that JNK activation is required for caspase 8 activation and apoptotic cell death induced by luteolin and TNFa.
Ectopic expression of A20, c-IAP1 and dominant negative forms of JNKK1 and JNKK2 prevents apoptosis induced by luteolin and TNFa
The above data collectively demonstrate that the reduced expression of antiapoptotic genes A20 and Figure 6 ) may contribute to apoptosis induced by luteolin and TNFa. Here, we used genetic approaches to further establish the causative link between these events. HeLa cells were transiently transfected with either myc-A20 or HA-c-IAP1 expression vector together with a red fluorescence protein construct (pDsRed) as a transfection marker. In addition, a vector expressing a viral protein cytokine response member A (CrmA) which is known to be a specific caspase 8 inhibitor (Muzio et al., 1997) were included as a positive control. As shown in Figure 7a , the successfully transfected cells emitted strong red fluorescence as seen under a fluorescence microscope. Following treatments with luteolin and TNFa, most of the cells transfected with pDsRed and pcDNA died. Overexpression of CrmA offered a complete protection against apoptotic cell death induced by luteolin and TNFa (Figure 7a and b) , confirming our earlier finding that such apoptosis is mediated by caspase 8 activation (Figure 3) . Overexpression of either A20 or c-IAP1 protein significantly protected cell death induced by luteolin and TNFa, although to a lesser extent than that of CrmA, further confirming the role of A20 and c-IAP1 in the sensitization effect of luteolin.
It has been well established that TNFa-mediated JNK activation is regulated by two upstream MAPK kinases: JNKK1 and JNKK2 (Davis, 2000) . The effectiveness of dominant negative forms of JNKK1 and JNKK2 were proven in HeLa cells when they successfully blocked TNF-mediated JNK activation using JNK kinase assay (data not shown). Here, cells with successful HA-JNKK1(DN) and HA-JNKK2(DN) transfection became largely resistant to apoptosis induced by luteolin and TNFa. Such findings, together with the pharmacological evidence from SP600125 (Figure 6 ), suggests that JNK plays a critical role in the sensitization effect of luteolin on TNFa-induced apoptosis.
Discussion
Luteolin is a common plant flavonoid. Previous studies have demonstrated the anticancer property of luteolin. For instance, it is capable of preventing 7,12-dimethylbenz[a]anthracene (DMBA)-and 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced mouse skin cancer (Ueda et al., 2003) or inducing cell cycle arrest and apoptosis in some human cancer cells in vitro (Huang et al., 1999; Ko et al., 2002) . In this study, we provided evidence that luteolin sensitizes TNFa-induced apoptosis in human colorectal and cervical cancer cells. Such sensitization is achieved via its inhibitory effect on NFkB activation, which in turn results in reduced expression of antiapoptotic NF-kB targets genes (A20 and c-IAP1), as well as augmented and prolonged JNK activation. Data from this study thus reveal a novel function of luteolin and enhance the value of luteolin as a useful anticancer agent.
There are several features in the sensitization effect of luteolin on TNFa-induced cell death. First, the sensitization is mainly achieved through enhanced activation of caspase 8, the initial caspase in the death receptor signaling pathway to induce typical apoptosis (Strasser and Newton, 1999) . Such notion is supported by the strong inhibitory effects on cell death offered by z-IETDfmk, a synthetic caspase 8 inhibitor (Figure 3a) as well as by the overexpression of CrmA (Figure 7) , a powerful and specific caspase 8 inhibitor (Muzio et al., 1997) . In contrast, the contribution of caspase 9 towards the sensitization process of luteolin is believed to be insignificant based on the marginal inhibitory activity of a caspase 9 inhibitor on apoptosis (data not shown). A recent study by Deng et al. (2003) has revealed a novel cell death pathway initiated by TNFa, which involves a sequential participation of JNK, Bid and Smac/ DIABLO. Thus, the exact role of mitochondria in the sensitization activity of luteolin remains to be further established. Second, although luteolin sensitized TNFainduced apoptosis in a similar pattern as ActD ( Figure  2a and b), they apparently act through different mechanisms. Luteolin did not block the expression level of c-myc as ActD or CHX did (Figure 2c ), indicating that luteolin is not a general gene expression inhibitor, but rather works through a specific mechanism. Third, the sensitization effect of luteolin is depending on luteolin administration schedule. As shown in Figure 1b , luteolin post-treatment failed to exert sensitization effect on TNFa-induced apoptosis, suggesting that this effect may be associated with the blockage of antiapoptotic gene expression elicited by TNFa.
NF-kB activation is the principal cell survival signaling triggered by TNFa through TNFR1. The antiapoptotic function of NF-kB is achieved through upregulation of its antiapoptotic target genes (Baldwin, 2001; Kucharczak et al., 2003) . Therefore, we reasoned that luteolin sensitizes TNFa-induced apoptosis via its inhibitory effect on the NF-kB signaling pathway. Such a hypothesis is supported by the finding that luteolin pretreatment efficiently blocked the transactivation of NF-kB as determined by the NF-kB luciferase assay (Figure 4a ), while post-treatment with luteolin did not inhibit NF-kB transactivation and subsequently failed to exert any sensitization effect (Figure 1b) . We also attempted to evaluate the effect of luteolin on upstream signaling events of NF-kB activation. To our surprise, luteolin did not affect IkBa degradation, p65 nuclear translocation and NF-kB-DNA binding (Figure 4b and c). Such findings are basically similar to the effect of luteolin on LPS-induced NF-kB activation in rat fibroblasts (Kim et al., 2003b) . In contrast, Xagorari et al. (2001) reported that, in macrophages, luteolin inhibited LPS-induced NF-kB activation via preventing IkBa degradation. Different cell types used in those studies may explain the different responses to the same stimulus. Some other flavonoids such as apigenin and flavopiridol have also been found to suppress TNFastimulated NF-kB transcriptional activity without affecting IkBa degradation in some human colorectal cancer non-small-cell lung carcinoma cells (Farah et al., 2003; Kim et al., 2003a) .
Then how does luteolin inhibit NF-kB transactivation? We next examined the effect of luteolin on the CBP-p65 interaction, which is known to be required for p65 transcriptional activation (Gerritsen et al., 1997) . Luteolin significantly inhibited TNFa-induced CBP-p65 interaction (Figure 4d ), which is similar to its effect on LPS-induced CBP-p65 interaction (Kim et al., 2003b) . At present, it is not clear how luteolin interrupts CBPp65 interaction. In the context of LPS signaling, luteolin could perhaps induce JNK and c-jun activation and thus sequester transcriptional coactivators (Kim et al., 2003b) . In this study, luteolin alone had only marginal effect on JNK activation (Figure 6a) . Furthermore, SP600125 (specific JNK inhibitor) failed to restore the suppressed NF-kB transactivation by luteolin (data not shown), suggesting that JNK activation is unlikely to be an important contributing factor in the inhibitory effect by luteolin on NF-kB activation. Based on the observation that p65 overexpression could overturn the cell death induced by luteolin and TNF (Figure 4e and f) , it is possible that luteolin may inhibit p65-CBP interaction by targeting p65, although the exact mechanism responsible for such action remains to be further identified.
Among various antiapoptotic genes regulated by NFkB, a number of them such as c-IAP1, c-IAP2, c-FLIP L , c-FLIP S and A20 have been well characterized to specifically inhibit caspase 8 activation (Krikos et al., 1992; Wang et al., 1998; Micheau et al., 2001) . As shown in Figure 3 , luteolin sensitizes TNFa-mediated cell death via enhanced caspase 8 activation. We thus postulated that luteolin may augment caspase 8 activation via targeting the above-mentioned antiapoptotic genes. In this study, both A20 and c-IAP1 were significantly upregulated by TNFa and were found to be markedly suppressed by luteolin ( Figure 5 ). More importantly, the ectopic expression of both A20 and c-IAP1 conferred significant protection against apoptosis induced by luteolin and TNFa (Figure 7 ). Zinc-finger protein A20 is a NF-kB inducible gene (Krikos et al., 1992) and one of its important functions is inhibition of TNFamediated apoptosis (Song et al., 1996; Lademann, et al., 2001) . A20-deficient cells have been reported to be highly susceptible to apoptosis induced by TNFa (Lee et al., 2000) . A recent study revealed that A20 is capable of interrupting the recruitment of TRADD and RIP into TNFR1, thus blocking both caspase 8 (cell death) and the NF-kB (cell survival) pathways (He and Ting, 2002) . On the other hand, in this study c-IAP1, but not c-IAP2, was also found to be an important modulator in the sensitization of luteolin on TNFa-induced apoptosis. Despite the high sequence similarity between c-IAP1 and c-IAP2, different specificities have been identified regarding their effects on apoptosis. For instance, c-IAP1, but not c-IAP2, is capable of directing the ubiquitylation of TRAF2 in TNF signaling .
One intriguing issue in TNF signaling is the role of JNK in TNF-mediated apoptosis. Recently, several lines of evidence have demonstrated that inhibition of NF-kB leads to prolonged JNK activation, which promotes TNFa-induced apoptosis (Tang et al., 2001; De Smaele et al., 2001) . In this study, luteolin pretreatment also augmented and prolonged TNFa-mediated JNK activation (Figure 6a ). Since luteolin alone has only marginal effect on JNK activation (Figure 6a ), such augmentation is most likely due to the inhibition by luteolin on TNFa-induced NF-kB transactivation (Figure 4a ). Suppressed NF-kB activation and subsequently diminished XIAP or GADD45b expression in luteolin-treated cells could account for the enhanced JNK activity (Tang et al., 2001; De Smaele et al., 2001) . Using both genetic and pharmacological approaches, we provided convincing evidence that the augmentation and prolongation of JNK activation play a critical role in apoptosis triggered by luteolin and TNFa (Figures 6 and 7) . The exact mechanisms for JNK-mediated apoptosis may vary depending on the cellular context and the nature of stimuli. In UV-induced apoptosis, JNK is an important component in mitochondrial apoptotic pathway (Tournier et al., 2000) . On the other hand, a recent study (Deng et al., 2003) showed that JNK is required to relieve the inhibition imposed by TRAF2-c-IAP1 on caspase 8 activation triggered by TNFa. This newly identified role of JNK in TNFa-induced apoptosis helps to explain our observation that the specific JNK inhibitor (SP600125) prevented caspase 8 activation in cells treated with luteolin followed by TNFa (Figure 6b ).
In conclusion, we have highlighted a novel function of luteolin by demonstrating that luteolin interferes the TNF signaling pathway and markedly sensitizes human cancer cells to TNFa-induced apoptosis. Such sensitization is closely associated with the inhibitory effect of luteolin on NF-kB activation, resulting in downregulation of some key antiapoptotic genes such as A20 and c-IAP1, as well as augmented and prolonged JNK activation induced by TNFa. Therefore, data from this study provide important insights for the understanding of the molecular mechanisms involved in the anticancer activity of luteolin.
Materials and methods
Cell culture and treatment
Human colorectal cancer cells COLO205, HCT116 were obtained from ATCC and maintained in RPMI1640 medium (Sigma) supplemented with 10% fetal bovine serum (FBS) (Hyclone) and antibiotics. Human cervix cancer cells HeLa (from ATCC) were maintained in Dulbecco's modified Eagle's medium (DMEM) (Sigma) containing 10% FBS and antibiotics. Treatment details with luteolin (Sigma) and TNFa (Sigma) were illustrated in figure legends.
Measurement of cell death and apoptosis
Percentage of the hypodiploid cells or sub-G1 cells were measured as a general parameter for cell death as described previously . Various approaches were used to assess the specific parameters of apoptosis, including (i) poly(ADP-ribose) polymerase (PARP) cleavage using Western blot; (ii) DNA fragmentation using agarose gel electrophoresis and (iii) cell morphological changes with acridine orange (AO) and ethidium bromide (EB) staining (McGahon et al., 1995) .
Caspase 3-like and caspase 8 activity assay
Apo-one homogeneous caspase 3/7 assay kit (Promega) was used to measure the caspase 3-like activity according to the manufacturer's protocol. For the measurement of caspase 8 activity, cells were collected, pelleted and lysed in lysis buffer (10 mM HEPES, pH 7.4, 42 mM KCl, 5 mM MgCl 2 , 1 mM DTT and 0.1% Triton X-100). The whole-cell lysate containing 50 mg protein was incubated with 5 mM Ac-IETD-AMC (Biomol) in a total volume of 200 ml of reaction buffer (50 mM HEPES, pH 7.0, 10% glycerol, 0.1% CHAPS, 2 mM EDTA, 2 mM dithiothreitol) at 371C for 1 h. The fluorescence intensity of released AMC was then quantitated using a spectrofluorimeter (excitation 390 and emission 510 nm). Caspase activities were presented as relative values of the fluorescence intensity over the control group.
Transient transfection
HeLa cells were transiently transfected with either pcDNA (Clontech), p65-GFP (kindly provided by Dr W Greene, UCSF), myc-A20 (kindly provided by Dr A Ting, Mount Sinai School of Medicine, NY, USA), HA-c-IAP1, CrmA or dominant negative forms of both HA-JNKK1 and HA-JNKK2 (kindly provided by Dr ZG Liu, NIH), using the Lipofectamine transfection reagent (Invitrogen). A red fluorenscent protein expression vector (pDsRed, Clontech) or green fluorenscent protein EGFP (Clontech) was cotransfected as a transfection marker. After 24 h of transfection, the cells were pretreated with luteolin (40 mM Â 2 h) followed by TNFa (15 ng/ml Â 24 h). Cell death was determined by morphological changes examined and recorded using an inverted fluorescent microscopy (Nikon).
NF-kB luciferase reporter assay
COLO205 cells were transiently transfected with the NF-kBdependent luciferase reporter construct and b-gal construct (Clontech) using the Lipofectamine and PLUS transfection reagent according to the manufacturer's protocol (Invitrogen). Luciferase activity was determined using the luciferase assay system (Promega) and normalized with the b-galactosidase enzyme activity for transfection efficiency.
Preparation of whole-cell lysate, cell fractionation, coimmunoprecipitation and Western blot Whole-cell lysate was obtained using M2 lysis buffer (20 mM Tris, pH 7.4, 0.5% NP-40, 250 mM NaCl, 3 mM EDTA, 3 mM EGTA, 2 mM dithiothreitol, 0.5 mM phenylmethylsulfonyl fluoride, 20 mM b-glycerol phosphate, 1 mM sodium vanadate and 1 mg/ml leupeptin) (Lin et al., 1999) . Cytosol and nuclear fractions were prepared based on a protocol described previously with modification (Wu et al., 2002) . In brief, the treated cells were harvested and centrifuged at 600 g for 5 min. The pellet was washed with ice-cold PBS and resuspended in 100 ml of buffer (20 mM HEPES, 10 mM KCl, 1.5 mM MgCl 2 , 1 mM EDTA, 1 mM EGTA, 1 mM dithiothreitol, 0.1 mM phenylmethylsulfonyl fluoride, 250 mM sucrose, pH 7.5), homogenized by a syringe with a 27-guage needle for 15-20 times. The lysate was centrifuged at 50 g for 10 min to spin down the intact cells. The resulting supernatant was centrifuged at 1000g for 10 min. The nuclear-rich pellet was resuspended in 50 ml buffer. The supernatant was further centrifuged at 15 000g for 1 h to obtain cytosolic fraction. The coimmunoprecipitation experiment was performed using CBP antibody for detecting CBPp65 interaction, based on a report method (Kim et al., 2003b) . For Western blot, equal amount of proteins were fractionated on SDS-polyacrylamide gel in the Mini-PROTEAN II system (Bio-Rad) and blotted onto PVDF membrane (Millipore). After blocked with 5% nonfat milk in TBST (10 mM Tris-HCl, pH 7.5, 100 mM NaCl, 0.1% Tween 20), the membrane was probed with various antibodies and developed with enhanced chemiluminescence (Pierce) using a Kodak Image Station (Kodak).
Electrophoretic mobility shift assay (EMSA)
The DNA-binding activity of nuclear proteins was tested according to established method with modifications (Hehner et al., 1998) . NF-kB consensus oligonucleotides (5 0 -AGTT GAGGGGACTTTCCCAGGC-3 0 and 3 0 -TCAACTCCCCT GAAAGGGTCCG-5 0 ) (Promega) were labeled with p32-gATP using T4 kinase (Invitrogen). Equal amounts of nuclear protein (5 mg) were incubated with 100 000 c.p.m. labeled NFkB oligonucleotides in 5 Â reaction buffer (100 mM HEPES/ KOH, pH 7.9, 20% glycerol, 1 mM dithiothreitol and 300 mM KCl) for 30 min at room temperature, in the presence of 2 mg poly(dI-dC) and 2 mg bovine serum album in a total volume of 20 ml. For the supershift experiment, 2 mg anti-p65 antibody was added into the binding reaction mixture before adding the labeled probe. The DNA-protein complexes were resolved on a 5% polyacrylamide gel. Gels were then dried and exposed to an X-ray film (Kodak) at À801C overnight.
RNA extraction and RT-PCR
RNA extraction was carried out using a total RNA extraction kit (Purescript), following the instructions from the manufacturer. 5 mg of total RNA from each sample were subjected to reverse transcription using M-MLV reverse transcriptase (Promega). For PCR, the amplification reaction was carried with 200 pmol of each primer, 200 mM of each dNTPs and 0.5 U of Tag DNA polymerase II (Promega). The PCR conditions were optimized to achieve exponential amplification in which the PCR product formation is proportional to the starting cDNA. The primers of human A20 (He and Ting, 2002) , c-IAP1, c-IAP2 (Sonoda et al., 2000) , c-FLIP L , c-FLIP S (Petak et al., 2000) and glyceraldehydes-3-phosphate dehydrogenase (G3PDH) (Mafune et al., 1999) were based on literature. After PCR, products were size fractionated using 1.8% agarose gel and visualized by EB staining.
Statistical analysis
The numeric data are presented as mean7s.d. from at least three sets of independent experiments. The differences among different groups were examined using a one-way ANOVA with Scheffe's test (SPSS 11) and Po0.05 was considered statistically significant.
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